$24.200
+1.120 (+4.63%)收盘时
ATTO 同业对比
In the context of the broader market, ATTO competes directly with industry leaders such as IVA and DSGN. With a market capitalization of $956.10M, it holds a significant position in the sector. When comparing efficiency, ATTO's gross margin of N/A stands against IVA's 100.00% and DSGN's N/A. Such benchmarking helps identify whether Attovia Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Attovia Therapeutics Inc 财务表现
Attovia has shown a gross margin of 0% for Q1 2026, indicating no revenue generation yet, but it has a strong current ratio of 13.94, suggesting good liquidity. The forward P/E ratio of 4.81 indicates potential for future earnings growth.
Financials
FY2026Q2
450.00K
Total Revenue
FY2026Q2
-21.80M
Operating Profit
FY2026Q1
YoY:
+23.13%
-18.66M
Net Income after Tax
FY2026Q1
YoY:
+19.44%
-0.43
EPS - Diluted
FY2025Q4
100.00
Gross Profit Margin - %
FY2025Q4
-4.56K
FCF Margin - %
FY2025Q4
-4.49K
Net Margin - %
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。